Latest Interviews
Showing 1–13 of 13 transcripts.
Clear all filters- a16z59 min
Taking Bold Bets: NIH and the Future of Biomedical Science
Dr. Jay Bhattacharya, Erik Torenberg, Vineeta Agarwala, Jorge Conde
Secretary Xavier Becerra announced a $50 million federal investment to launch the Autism Data Science Initiative, selecting 13 teams from 250 applicants to address the rising prevalence of autism and the lack of effective therapies. Concurrently, the NIH is implementing comprehensive reforms to resolve the scientific replication crisis, centralize peer review, and prioritize early-career investigators to foster high-risk innovation. These strategic shifts aim to rebuild public trust through transparent communication, integrate AI for capacity augmentation, and tackle chronic diseases while ensuring rigorous, reproducible medical standards.
- a16z56 min
Faster Science, Better Drugs
Erik Torenberg, Patrick Hsu, Jorge Conde
ARC Institute is establishing a physical hub to integrate machine learning with diverse biological disciplines, aiming to solve complex diseases like Alzheimer's by simulating human cells as digital foundations. Patrick O'Brian leads this effort to transition biological discovery from slow physical experiments to high-speed computation, targeting a "virtual cell" capable of predicting cellular perturbations with 90% accuracy. To validate this progress, the organization has launched the $100,000 Virtual Cell Challenge, seeking to replace traditional trial-and-error methods with AI-driven models that can replicate historic scientific breakthroughs.
- a16z25 min
Mastering Your Data with Sajith Wickramasekara
Sajith Wickramasekara, Jorge Conde, Jay Rughani
Founded in 2012 by a software engineer before CRISPR's mainstream adoption, Benchling has scaled into a platform serving over 200,000 scientists across 32 countries with $200 million in annualized revenue. The company evolved from a productivity tool into an essential data infrastructure provider, addressing the critical lack of structured data required to unlock AI's potential for accelerating drug discovery and manufacturing. Future strategies focus on unifying this aggregated data into a cohesive ecosystem to optimize therapeutic development from molecule design through clinical approval.
- a16z25 min
Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde
Jorge Conde of a16z Bio + Health proposes "programming medicine" as a paradigm shift that reuses delivery platforms like SpaceX rockets to accelerate the development of genetic therapies beyond traditional bespoke drug cycles. This approach, validated by the recent FDA approval of a CRISPR-based sickle cell treatment achieved in just over a decade, aims to transform biological manufacturing through regulatory adaptability and engineering precision. Despite current hurdles regarding permanent safety, complex logistics, and multi-million dollar costs, the strategy seeks to apply exponential scaling to reduce treatment prices from millions to thousands of dollars for broader patient access.
- a16z19 min
Healthcare Has Left the Building
A structural transformation is dissolving traditional silos between payers, providers, and technology firms to shift care from centralized hospitals to home settings while leveraging mobile diagnostics and AI-driven logistics. Major market entrants are challenging established models through value-based care initiatives and programmed therapies that enable proactive monitoring and personalized treatments like gene editing. This evolution modernizes the medical ecosystem to prioritize patient outcomes and efficiency, though the fundamental human need for care remains the driving force behind these technological accelerations.
- a16z41 min
a16z Podcast | What's in the Water at the George Church Lab?
George Church, Jorge Conde, Hannah
George Church analyzes the 2018 Chinese CRISPR baby case as a pivotal, government-tolerated precedent for germline editing that bypassed ethical moratoriums through a technical strategy of *CCR5* knockout for HIV resistance. He predicts that, similar to the 1978 test-tube baby phenomenon, this "n of 1" success will accelerate adoption and regulation rather than halt research, shifting the field from treatment toward preventative genomic medicine. While Church advocates for robust privacy frameworks like zero-dollar genomes and encryption to overcome security barriers, his broader vision prioritizes environmental applications like mammoth de-extinction over non-therapeutic human editing.
- a16z36 min
a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Amy Abernethy, Christina Lopes, Jorge Conde, Sonal
Amy Abernethy has been selected as the new Principal Deputy Commissioner of the FDA, where she aims to advance personalized medicine and accelerate evidence generation following her tenure at Flatiron Health. Her appointment aligns with the growing adoption of One Health strategies, a platform co-founded by Cristina Lopez that leverages spontaneous canine cancer data to validate human therapies. By treating dogs as natural clinical models with fully functional immune systems, this initiative promises to save costs in drug development and improve outcomes for both veterinary and human patients through shared real-world evidence.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.
- a16z32 min
a16z Podcast | The Scientific Revolution of Ancient DNA
Jorge Conde, David Reich, Hanne Tidnam, Hannah
Leveraging a five-year revolution in ancient DNA sequencing that reduced costs and expanded sample sizes to millions, researchers have reconstructed full genomes to reveal archaic human populations like the Denisovans and overturn the "Mitochondrial Eve" genetic barrier. This data has fundamentally shifted the understanding of human history from a single trunk model to a complex mosaic of repeated migrations, such as the 4,500-year-old mass turnover replacing 90% of the British population, while simultaneously exposing genomic signatures of historical inequality and sex-biased social structures. By tracing these deep population shifts and correcting Eurocentric sampling biases, the field now provides a critical time-series for analyzing biological responses to environmental changes and correcting the inaccuracies of traditional family tree models.
- a16z27 min
a16z Podcast | Shifting Risk Mindsets, From Tech to Bio
Vijay Pande, Jorge Conde, Jeff Low, Jeffrey Lowe
This event guides tech founders through the critical challenges of translating their innovations into the biotechnology sector, emphasizing the necessity of treating biotech firms as data-driven enterprises. It details strategies to avoid operational pitfalls like "death by a thousand pilots" and outlines structural frameworks, such as LLC ring-fencing, to protect platform value while developing proprietary assets. Furthermore, the session provides actionable insights on diagnostics reimbursement, early validation "kill tests," and aligning hybrid investor syndicates to ensure sustainable growth in a high-barrier market.
- a16z8 min
a16z Podcast | On Recent Consolidation in the Healthcare Industry
Jorge Conde, Vijay Pande, Jeffrey Low
Major healthcare players are driving industry consolidation through vertical integration strategies exemplified by Walmart's potential Humana acquisition and the Amazon-JP Morgan-Berkshire consortium. These moves aim to collapse the value chain from manufacturers to insurers, though speakers distinguish between locally dominant retailers and geographically dispersed employer groups regarding their pricing power. As Amazon targets opaque PBM margins without acquiring marquee assets, the market anticipates new entrepreneurial opportunities in specialized genomic and cell therapy logistics to manage rising treatment costs.
- a16z7 min
a16z Podcast | Players and Paths for Healthcare Startups
Healthcare startups navigate a complex, multi-stage landscape by aligning their go-to-market strategies with either therapeutic, diagnostic, or tool-based verticals to overcome distinct regulatory and reimbursement hurdles. Founders must determine whether to pursue internal drug development or leverage non-exclusive licensing for platforms, as seen in the billion-dollar valuation success of Atomab or the industry dominance of Illumina. This approach requires immediately defining specific evidence needs, regulatory pathways, and payment entities to ensure viable product commercialization in a fragmented market.
- a16z22 min
a16z Podcast | When (and How) Biology Becomes Engineering
The event details the transformative shift in biology from a stochastic, discovery-based science to a standardized engineering discipline that treats biological components as predictable, interchangeable parts. Interdisciplinary innovation and machine learning now drive this transition by enabling repeatable design-build-refine cycles that replace traditional high-risk experimentation with data-driven predictability. This engineering mindset aims to commercialize biological platforms through measurable success rates and sustainable infrastructure, ultimately making previously impossible medical and industrial goals achievable through compounding technological improvements.